- Ophthotech - Buy This Multibagger Today
- How The Global Pharma Industry Will Shape Up In The Next 5 Years?
- Glivec Generics May Be Delayed In The U.S. - Buy Novartis
- Daiichi Sankyo's Factor Xa Inhibitor Edoxaban Clears Phase III Hurdle - A Major Threat To Xarelto And Eliquis
- Eliquis (Apixaban) Approved In Europe - A Blockbuster Opportunity For Bristol-Myers, Pfizer
This user currently has no profile.
Over 10 years of experience as a sell side analyst covering Big Pharma names. Specialise in contrarian calls with a very good success rate. Now working as buy side analyst with a proprietary fund.
- Description: Professional Blogger. Trading frequency: Infrequent
- Interests: Stocks - long
PharmaInvest PharmaInvest is intended to provide global pharmaceutical intelligence with an objective to help fund managers making prudent investment decisions. The focus is to look at undervalued stocks and identify triggers ahead of competition to achieve multi-bagger returns.
pharmainvest Pharmainvest is an online publication targeted to provide global pharmaceutical intelligence to Industry professionals and Pharma focused fund managers.
Currently, you have no book details. Click edit to add book details.
Latest Comments more »
- Sure, we are in the process... on Ophthotech - Buy This Multibagger Today
- The company is conducting a... on Ophthotech - Buy This Multibagger Today
- A label is still awaited. t... on Daiichi Sankyo's Factor Xa Inhibitor Edoxaban C...
- Teva would be the first com... on Teva Pharmaceutical Industries' CEO Discusses 2...
- Filing in the US will happe... on Forxiga For Type 2 Diabetes Is A Potential Bloc...
Latest comments on Pharma's Articles
LATEST ARTICLES & INSTAPOSTS more »